|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
KR101681818B1
(ko)
|
2011-08-23 |
2016-12-01 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
US10077315B2
(en)
|
2013-02-05 |
2018-09-18 |
Engmab Sàrl |
Bispecific antibodies against CD3 and BCMA
|
|
KR20180023035A
(ko)
|
2013-02-26 |
2018-03-06 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
KR20230004939A
(ko)
|
2014-02-07 |
2023-01-06 |
맥마스터 유니버시티 |
3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
|
|
EP3110848B1
(en)
|
2014-02-28 |
2024-02-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an il-4r antagonist
|
|
DK3177643T3
(da)
|
2014-08-04 |
2019-07-15 |
Hoffmann La Roche |
Bispecifikke T-celle-aktiverende antigenbindende molekyler
|
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
|
|
DK4141032T3
(da)
|
2014-11-20 |
2024-08-05 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
|
|
DK3221356T3
(da)
|
2014-11-20 |
2020-11-02 |
Hoffmann La Roche |
T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
|
|
EP3023437A1
(en)
*
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
DK3221357T3
(da)
|
2014-11-20 |
2020-08-10 |
Hoffmann La Roche |
Fælles letkæder og fremgangsmåder til anvendelse
|
|
EP3029068A1
(en)
*
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
AU2016248946C1
(en)
|
2015-04-13 |
2024-10-17 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
|
RU2706582C2
(ru)
|
2015-04-13 |
2019-11-19 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток
|
|
IL303905A
(en)
|
2015-05-18 |
2023-08-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR programming using fusion proteins
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
IL298041B2
(en)
|
2015-08-17 |
2025-10-01 |
Janssen Pharmaceutica Nv |
Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
KR102850929B1
(ko)
|
2015-12-09 |
2025-08-27 |
에프. 호프만-라 로슈 아게 |
항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
|
|
ES2837428T3
(es)
|
2016-01-08 |
2021-06-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
|
|
SG11201805770UA
(en)
*
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
HK1259075A1
(zh)
|
2016-02-17 |
2019-11-22 |
Seattle Genetics, Inc. |
Bcma抗体和其用以治疗癌症和免疫病症的用途
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ｔ細胞二重特異性分子
|
|
SG11201808403SA
(en)
*
|
2016-04-01 |
2018-10-30 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
|
PT3436030T
(pt)
|
2016-04-01 |
2022-11-18 |
Amgen Inc |
Recetores quiméricos e métodos para a sua utilização
|
|
PL3436079T3
(pl)
|
2016-04-01 |
2021-12-20 |
Kite Pharma, Inc. |
Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
KR20190036551A
(ko)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
|
|
JP7109789B2
(ja)
|
2016-08-02 |
2022-08-01 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
|
|
CN118141914A
(zh)
|
2016-09-01 |
2024-06-07 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
UA126384C2
(uk)
*
|
2016-09-14 |
2022-09-28 |
Тенеобіо, Інк. |
Антитіло, яке зв'язує cd3
|
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
ES2875959T3
(es)
|
2016-10-07 |
2021-11-11 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
|
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
NZ795790A
(en)
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-BCMA heavy chain-only antibodies
|
|
IL267567B2
(en)
*
|
2016-12-22 |
2024-08-01 |
Daiichi Sankyo Co Ltd |
Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
|
|
US11525006B2
(en)
*
|
2017-01-23 |
2022-12-13 |
Crage Medical Co., Limited |
BCMA-targeting antibody and use thereof
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
WO2018145075A1
(en)
*
|
2017-02-06 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
|
EP3579848B1
(en)
|
2017-02-08 |
2024-10-30 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
SG11201907253VA
(en)
*
|
2017-02-10 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding bcma, nkg2d and cd16
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
CN108456250B
(zh)
*
|
2017-02-17 |
2025-11-28 |
恺兴生命科技(上海)有限公司 |
靶向il-13ra2的抗体及其应用
|
|
JP7685821B2
(ja)
|
2017-02-20 |
2025-05-30 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
|
|
AU2018228719B2
(en)
|
2017-02-28 |
2023-03-30 |
Affimed Gmbh |
Tandem diabody for CD16A-directed NK-cell engagement
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
JP7356354B2
(ja)
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
EP3625253A4
(en)
|
2017-05-16 |
2021-03-24 |
Scalmibio, Inc. |
ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
|
|
US11970540B2
(en)
|
2017-06-20 |
2024-04-30 |
Teneobio, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
CA3065951A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
KR20200068647A
(ko)
|
2017-08-11 |
2020-06-15 |
시티 오브 호프 |
트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CA3075716A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN111094353A
(zh)
|
2017-09-14 |
2020-05-01 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
US11401334B2
(en)
|
2017-09-14 |
2022-08-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor
|
|
TWI713843B
(zh)
*
|
2017-09-30 |
2020-12-21 |
大陸商科濟生物醫藥(上海)有限公司 |
標靶bcma的抗體及其應用
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
TW201922774A
(zh)
|
2017-11-15 |
2019-06-16 |
瑞士商諾華公司 |
標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法
|
|
AU2018375738A1
(en)
|
2017-11-30 |
2020-06-11 |
Novartis Ag |
BCMA-targeting chimeric antigen receptor, and uses thereof
|
|
MX2020006494A
(es)
|
2017-12-22 |
2020-11-24 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22.
|
|
AU2018395273A1
(en)
*
|
2017-12-27 |
2020-08-13 |
Teneobio, Inc. |
CD3-delta/epsilon heterodimer specific antibodies
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
MX2020008336A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
|
|
CN118772288A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
EP3759146A1
(en)
|
2018-03-02 |
2021-01-06 |
CDR-Life AG |
Trispecific antigen binding proteins
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
BR112020019795A2
(pt)
|
2018-03-30 |
2021-01-05 |
Merus N.V. |
Anticorpo multivalente
|
|
CA3095373A1
(en)
|
2018-04-13 |
2019-10-17 |
Affimed Gmbh |
Nk cell engaging antibody fusion constructs
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
SG11202011080QA
(en)
|
2018-05-11 |
2020-12-30 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
CA3100118A1
(en)
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
CN118459594A
(zh)
|
2018-06-01 |
2024-08-09 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
PT3823665T
(pt)
|
2018-07-19 |
2024-02-26 |
Regeneron Pharma |
Recetores antigénicos quiméricos que possuem uma especificidade para o bcma e utilizações dos mesmos
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
BR112020024074A2
(pt)
|
2018-07-20 |
2021-02-17 |
Teneobio, Inc. |
anticorpos de cadeia pesada com ligação a cd19
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
SG11202101298XA
(en)
|
2018-08-08 |
2021-03-30 |
Dragonfly Therapeutics Inc |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
SG11202101825QA
(en)
|
2018-08-31 |
2021-03-30 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN109293772B
(zh)
*
|
2018-09-25 |
2020-09-29 |
上海邦耀生物科技有限公司 |
靶向bcma蛋白的抗体、嵌合抗原受体和药物
|
|
CN112955748A
(zh)
|
2018-10-31 |
2021-06-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的方法
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
KR20210106521A
(ko)
*
|
2018-12-20 |
2021-08-30 |
세다르스-신나이 메디칼 센터 |
기관 이식체의 만성 항체 매개된 거부의 치료에서 클라자키주맙
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
SG11202107825WA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
WO2020191346A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
WO2020191316A1
(en)
|
2019-03-21 |
2020-09-24 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
KR20210149076A
(ko)
|
2019-04-05 |
2021-12-08 |
테네오바이오, 인코포레이티드 |
Psma에 결합하는 중쇄 항체
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
JP2022531185A
(ja)
|
2019-04-30 |
2022-07-06 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
|
|
EA202193040A1
(ru)
*
|
2019-05-03 |
2022-03-25 |
Селджен Корпорэйшн |
Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
EP4010001A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
SG11202113310UA
(en)
|
2019-08-05 |
2021-12-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
CN120204384A
(zh)
|
2019-08-06 |
2025-06-27 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和相关方法
|
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
|
CN114728065A
(zh)
|
2019-11-26 |
2022-07-08 |
上海岸迈生物科技有限公司 |
针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
|
|
JP2023506958A
(ja)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
|
|
EP4076503A4
(en)
*
|
2019-12-20 |
2024-04-03 |
MedImmune, LLC |
Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
EP4106819A1
(en)
|
2020-02-21 |
2022-12-28 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
WO2021173442A1
(en)
*
|
2020-02-24 |
2021-09-02 |
The Regents Of The University Of California |
In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
AR121461A1
(es)
|
2020-02-27 |
2022-06-08 |
Novartis Ag |
Métodos para la fabricación de células que expresan el receptor de antígeno quimérico
|
|
TWI838621B
(zh)
|
2020-04-29 |
2024-04-11 |
美商泰尼歐萬公司 |
具有經修飾重鏈恆定區之多特異性重鏈抗體
|
|
JP7625007B2
(ja)
|
2020-04-29 |
2025-01-31 |
テネオバイオ， インコーポレイテッド |
重鎖定常領域が修飾された多重特異性重鎖抗体
|
|
AR122018A1
(es)
|
2020-05-06 |
2022-08-03 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a nkg2d, cd16 y clec12a
|
|
AU2021272291A1
(en)
|
2020-05-11 |
2023-02-02 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
EP4153317A1
(en)
|
2020-05-19 |
2023-03-29 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
|
AU2021288224A1
(en)
|
2020-06-11 |
2023-01-05 |
Novartis Ag |
ZBTB32 inhibitors and uses thereof
|
|
BR112022025856A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CR20220656A
(es)
|
2020-06-30 |
2023-03-01 |
Teneobio Inc |
Unión de anticuerpos multiespecíficos a bcma
|
|
KR20230047361A
(ko)
|
2020-07-01 |
2023-04-07 |
아르스 파마슈티컬스 인크. |
항-asgr1 항체 접합체 및 이의 용도
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202227124A
(zh)
|
2020-08-21 |
2022-07-16 |
瑞士商諾華公司 |
用於體內產生ｃａｒ表現細胞的組成物和方法
|
|
WO2022090556A1
(en)
|
2020-11-02 |
2022-05-05 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
CN117222663A
(zh)
|
2021-03-03 |
2023-12-12 |
蜻蜓疗法股份有限公司 |
使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
|
|
EP4301418A1
(en)
*
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
US20240158505A1
(en)
*
|
2021-03-26 |
2024-05-16 |
Theranotics Co., Ltd. |
B7-h3 antibody or antigen-binding fragment thereof, and use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
US20240384293A1
(en)
|
2021-04-27 |
2024-11-21 |
Novartis Ag |
Viral vector production system
|
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
|
US12016923B2
(en)
|
2021-06-01 |
2024-06-25 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 T cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
CA3227515A1
(en)
|
2021-08-03 |
2023-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
|
AU2022330406A1
(en)
|
2021-08-20 |
2024-03-07 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
|
US20240360216A1
(en)
*
|
2021-09-03 |
2024-10-31 |
Novoprotein Scientific Inc. |
Anti-cd3 humanized antibody
|
|
EP4412713A1
(en)
|
2021-10-05 |
2024-08-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapies for treating cancer
|
|
KR20240099376A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
|
|
JP2025503949A
(ja)
|
2022-01-25 |
2025-02-06 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンに対する併用療法
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
KR20250067121A
(ko)
|
2022-07-08 |
2025-05-14 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
Cnx 항원-결합 분자
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024121711A1
(en)
|
2022-12-05 |
2024-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treatment using b-cell maturation antigen antagonists
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
AU2024276994A1
(en)
|
2023-05-24 |
2025-10-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250262300A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|